Forte Biosciences (FBRX) Registration Filing summary

Company overview and business model

• Operates as a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases.

• Lead product candidate, FB102, is an anti-CD122 monoclonal antibody targeting key immune pathways.

• FB102 is being developed for celiac disease, with additional potential in vitiligo, alopecia areata, and type 1 diabetes.

• Phase 1 trials in healthy volunteers showed a good safety profile and significant pharmacodynamic effects; a celiac disease trial is ongoing with results expected in Q2 2025.

Financial performance and metrics

• The company qualifies as a smaller reporting company, allowing for reduced disclosure requirements.

• No dividends have been paid and there are no current plans to pay dividends.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used at management's discretion, with specific uses detailed in future prospectus supplements.